1. CrohnBB. Notes on the Evolution of a Medical Specialist: 1907–1965. Crohn Research Foundation; 1984.

2. CrohnBB, GinzburgL, OppenheimerGD. Landmark article Oct 15, 1932. Regional ileitis. A pathological and clinical entity. By Burril B. Crohn, Leon Ginzburg, and Gordon D. Oppenheimer. JAMA1984;251:73. CrossRef

3. SimonC. Inflammatory bowel disease. InnovAiT2008;1:615.

4. DalzielTK. Chronic interstitial enteritis. Br Med J1913;2:1068.

5. VasiliauskasEA, KamLY, KarpLC, et al.Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut2000;47:487. CrossRef

6. FarmerRG, HawkWA, TurnbullRBJr. Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology1975;68:627.

7. JostinsL, RipkeS, WeersmaRK, et al.Host‐microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature2012;491:119. CrossRef

8. KappelmanMD, Rifas‐ShimanSL, KleinmanK, et al.The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol2007;5:1424. CrossRef

9. LoftusCG, LoftusEVJr, HarmsenWS, et al.Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. Inflamm Bowel Dis2007;13:254. CrossRef

10. MolodeckyNA, SoonIS, RabiDM, et al.Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology2012;142:46, e30. CrossRef

11. MolodeckyNA, PanaccioneR, GhoshS, et al.Challenges associated with identifying the environmental determinants of the inflammatory bowel diseases. Inflamm Bowel Dis2011;17:1792. CrossRef

12. GearryRB, RichardsonAK, FramptonCM, et al.Population‐based cases control study of inflammatory bowel disease risk factors. J Gastroenterol Hepatol2010;25:325. CrossRef

13. MontgomerySM, MorrisDL, PounderRE, et al.Asian ethnic origin and the risk of inflammatory bowel disease. Eur J Gastroenterol Hepatol1999;11:543. CrossRef

14. ProbertCS, JayanthiV, PinderD, et al.Epidemiological study of ulcerative proctocolitis in Indian migrants and the indigenous population of Leicestershire. Gut1992;33:687. CrossRef

15. Gower‐RousseauC, SalomezJL, DupasJL, et al.Incidence of inflammatory bowel disease in northern France (1988–1990). Gut1994;35:1433. CrossRef

16. ShivanandaS, Lennard‐JonesJ, LoganR, et al.Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC‐IBD). Gut1996;39:690. CrossRef

17. LindbergE, JarnerotG, HuitfeldtB. Smoking in Crohn's disease: effect on localisation and clinical course. Gut1992;33:779. CrossRef

18. MahidSS, MinorKS, SotoRE, et al.Smoking and inflammatory bowel disease: a meta‐analysis. Mayo Clin Proc2006;81:1462. CrossRef

19. CosnesJ, CarbonnelF, BeaugerieL, et al.Effects of cigarette smoking on the long‐term course of Crohn's disease. Gastroenterology1996;110:424. CrossRef

20. NgSC, BernsteinCN, VatnMH, et al.Geographical variability and environmental risk factors in inflammatory bowel disease. Gut2013;62:630. CrossRef

21. ReifS, LavyA, KeterD, et al.Lack of association between smoking and Crohn's disease but the usual association with ulcerative colitis in Jewish patients in Israel: a multicenter study. Am J Gastroenterol2000;95:474. CrossRef

22. KaplanGG, JacksonT, SandsBE, et al.The risk of developing Crohn's disease after an appendectomy: a meta‐analysis. Am J Gastroenterol2008;103:2925. CrossRef

23. BernsteinCN, BlanchardJF, KliewerE, et al.Cancer risk in patients with inflammatory bowel disease: a population‐based study. Cancer2001;91:854. CrossRef

24. VirtaL, AuvinenA, HeleniusH, et al.Association of repeated exposure to antibiotics with the development of pediatric Crohn's disease–a nationwide, register‐based finnish case‐control study. Am J Epidemiol2012;175:775. CrossRef

25. AnanthakrishnanAN, HiguchiLM, HuangES, et al.Aspirin, nonsteroidal anti‐inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study. Ann Intern Med2012;156:350. CrossRef

26. ReddyD, SiegelCA, SandsBE, et al.Possible association between isotretinoin and inflammatory bowel disease. Am J Gastroenterol2006;101:1569. CrossRef

27. CrockettSD, PorterCQ, MartinCF, et al.Isotretinoin use and the risk of inflammatory bowel disease: a case‐control study. Am J Gastroenterol2010;105:1986. CrossRef

28. CrockettSD, GulatiA, SandlerRS, et al.A causal association between isotretinoin and inflammatory bowel disease has yet to be established. Am J Gastroenterol2009;104:2387. CrossRef

29. BernsteinCN, NugentZ, LongobardiT, et al.Isotretinoin is not associated with inflammatory bowel disease: a population‐based case‐control study. Am J Gastroenterol2009;104:2774. CrossRef

30. RiordanAM, RuxtonCH, HunterJO. A review of associations between Crohn's disease and consumption of sugars. Eur J Clin Nutr1998;52:229. CrossRef

31. ShodaR, MatsuedaK, YamatoS, et al.Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n‐6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. Am J Clin Nutr1996;63:741.

32. MartinGS, TapsellLC, BatterhamMJ, et al.Relative bias in diet history measurements: a quality control technique for dietary intervention trials. Public Health Nutr2002;5:537. CrossRef

33. ChanSS, LubenR, OlsenA, et al.Body mass index and the risk for Crohn's disease and ulcerative colitis: data from a European Prospective Cohort Study (the IBD in EPIC study). Am J Gastroenterol2013;108:575. CrossRef

34. WagtmansMJ, VerspagetHW, LamersCB, et al.Clinical aspects of Crohn's disease of the upper gastrointestinal tract: a comparison with distal Crohn's disease. Am J Gastroenterol1997;92:1467.

35. SilverbergMS, SatsangiJ, AhmadT, et al.Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol2005;19(Suppl A):5.

36. MelmedGY, ElashoffR, ChenGC, et al.Predicting a change in diagnosis from ulcerative colitis to Crohn's disease: a nested, case‐control study. Clin Gastroenterol Hepatol2007;5:602, 525. CrossRef

37. MowWS, VasiliauskasEA, LinYC, et al.Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology2004;126:414. CrossRef

38. HeikenenJB, WerlinSL, BrownCW, et al.Presenting symptoms and diagnostic lag in children with inflammatory bowel disease. Inflamm Bowel Dis1999;5:158. CrossRef

39. DevlinSM, YangH, IppolitiA, et al.NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. Gastroenterology2007;132:576. CrossRef

40. WeizmanAV, HuangBL, BerelD, et al.Serologic and genetic profiles suggest distinct immune pathways among patients with pyoderma gangrenosum and inflammatory bowel disease. Gastroenterology2012;142:S7. CrossRef

41. MillerMM. Ankylosing spondylitis, Reiter's syndrome, psoriatic arthritis, and arthritis of inflammatory bowel disease. Prim Care1984;11:271.

42. OrchardTR, WordsworthBP, JewellDP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut1998;42:387. CrossRef

43. MielantsH, VeysEM. HLA‐B27 related arthritis and bowel inflammation. Part 1. Sulfasalazine (salazopyrin) in HLA‐B27 related reactive arthritis. J Rheumatol1985;12:287.

44. MallasEG, MackintoshP, AsquithP, et al.Histocompatibility antigens in inflammatory bowel disease. Their clinical significance and their association with arthropathy with special reference to HLA‐B27 (W27). Gut1976;17:906. CrossRef

45. ShivashankarR, LoftusEVJr, TremaineWJ, et al.Incidence of spondyloarthropathy in patients with Crohn's disease: a population‐based study. J Rheumatol2012;39:2148. CrossRef

46. PalmO, MoumB, OngreA, et al.Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). J Rheumatol2002;29:511.

47. De VosM, CuvelierC, MielantsH, et al.Ileocolonoscopy in seronegative spondylarthropathy. Gastroenterology1989;96:339.

48. MielantsH, VeysEM, CuvelierC, et al.Ileocolonoscopic findings in seronegative spondylarthropathies. Br J Rheumatol1988;27(Suppl 2):95. CrossRef

49. MatzkiesFG, TarganSR, BerelD, et al.Markers of intestinal inflammation in patients with ankylosing spondylitis: a pilot study. Arthritis Res Ther2012;14:R261. CrossRef

50. WrightR, LumsdenK, LuntzMH, et al.Abnormalities of the sacro‐iliac joints and uveitis in ulcerative colitis. Q J Med1965;34:229.

51. HillRJ, BrookesDS, DaviesPS. Bones in pediatric Crohn's disease: a review of fracture risk in children and adults. Inflamm Bowel Dis2011;17:1223. CrossRef

52. VestergaardP, KroghK, RejnmarkL, et al.Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut2000;46:176. CrossRef

53. MintzR, FellerER, BahrRL, et al.Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis2004;10:135. CrossRef

54. DoctorP, SultanA, SyedS, et al.Infliximab for the treatment of refractory scleritis. Br J Ophthalmol2010;94:579. CrossRef

55. ThrashB, PatelM, ShahKR, et al.Cutaneous manifestations of gastrointestinal disease: part II. J Am Acad Dermatol2013;68:211 e1, 44. CrossRef

56. SiroyA, WasmanJ. Metastatic Crohn disease: a rare cutaneous entity. Arch Pathol Lab Med2012;136:329. CrossRef

57. ArdizzoneS, PuttiniPS, CassinottiA, et al.Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis2008;40(Suppl 2):S253. CrossRef

58. LapidusA, BangstadM, AstromM, et al.The prevalence of gallstone disease in a defined cohort of patients with Crohn's disease. Am J Gastroenterol1999;94:1261. CrossRef

59. NavaneethanU, ChoureA, VenkateshPG, et al.Presence of concomitant inflammatory bowel disease is associated with an increased risk of postcholecystectomy complications. Inflamm Bowel Dis2012;18:1682. CrossRef

60. MistilisSP. Pericholangitis and ulcerative colitis. I. Pathology, etiology, and pathogenesis. Ann Intern Med1965;63:1. CrossRef

61. O'TooleA, AlakkariA, KeeganD, et al.Primary sclerosing cholangitis and disease distribution in inflammatory bowel disease. Clin Gastroenterol Hepatol2012;10:439. CrossRef

62. BoonstraK, van ErpecumKJ, van NieuwkerkKM, et al.Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflamm Bowel Dis2012;18:2270. CrossRef

63. SinghS, KhannaS, PardiDS, et al.Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta‐analysis. Inflamm Bowel Dis2013;19:1631.

64. LindstromL, BobergKM, WikmanO, et al.High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia. Aliment Pharmacol Ther2012;35:451. CrossRef

65. EatonJE, SilveiraMG, PardiDS, et al.High‐dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol2011;106:1638. CrossRef

66. SinghS, TalwalkarJA. Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clin Gastroenterol Hepatol2013;11:898. CrossRef

67. FarrayeFA, OdzeRD, EadenJ, et al.AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology2010;138:738. CrossRef

68. OikonomouK, KapsoritakisA, EleftheriadisT, et al.Renal manifestations and complications of inflammatory bowel disease. Inflamm Bowel Dis2011;17:1034. CrossRef

69. KaneS, KhatibiB, ReddyD. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol2008;103:631. CrossRef

70. SigelA, BotticherR, WilhelmE. Urological complications in chronic inflammatory diseases of the bowel. Eur Urol1977;3:7.

71. BasseriB, EnayatiP, MarchevskyA, et al.Pulmonary manifestations of inflammatory bowel disease: case presentations and review. J Crohns Colitis2010;4:390. CrossRef

72. BernsteinCN, WajdaA, BlanchardJF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population‐based study. Gastroenterology2005;129:827. CrossRef

73. WengX, LiuL, BarcellosLF, et al.Clustering of inflammatory bowel disease with immune mediated diseases among members of a northern california‐managed care organization. Am J Gastroenterol2007;102:1429. CrossRef

74. SmithVM, MurphyR. Orofacial granulomatosis: three case reports illustrating the spectrum of disease and overlap with Crohn's disease. Clin Exp Dermatol2013;38:33. CrossRef

75. BouguenG, SiproudhisL, BretagneJF, et al.Nonfistulizing perianal Crohn's disease: clinical features, epidemiology, and treatment. Inflamm Bowel Dis2010;16:1431. CrossRef

76. BouguenG, TrouilloudI, SiproudhisL, et al.Long‐term outcome of non‐fistulizing (ulcers, stricture) perianal Crohn's disease in patients treated with infliximab. Aliment Pharmacol Ther2009;30:749. CrossRef

77. SwaminathA, LichtigerS. Dilation of colonic strictures by intralesional injection of infliximab in patients with Crohn's colitis. Inflamm Bowel Dis2008;14:213. CrossRef

78. GrahamDY, OpekunAR, WillinghamFF, et al.Visible small‐intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol2005;3:55. CrossRef

79. YangH, McElreeC, RothMP, et al.Familial empirical risks for inflammatory bowel disease: differences between Jews and non‐Jews. Gut1993;34:517. CrossRef

80. NobleCL, ArnottID. What is the risk that a child will develop inflammatory bowel disease if 1 or both parents have IBD?Inflamm Bowel Dis2008;14(Suppl 2):S22. CrossRef

81. MeiL, TarganSR, LandersCJ, et al.Familial expression of anti‐Escherichia coli outer membrane porin C in relatives of patients with Crohn's disease. Gastroenterology2006;130:1078. CrossRef

82. HassanC, ZulloA, De FrancescoV, et al.Systematic review: endoscopic dilatation in Crohn's disease. Aliment Pharmacol Ther2007;26:1457. CrossRef

83. SipponenT, NuutinenH, TurunenU, et al.Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES‐CD. Inflamm Bowel Dis2010;16:2131. CrossRef

84. RutgeertsP, GeboesK, VantrappenG, et al.Predictability of the postoperative course of Crohn's disease. Gastroenterology1990;99:956.

85. AnnunziataML, CavigliaR, PapparellaLG, et al.Upper gastrointestinal involvement of Crohn's disease: a prospective study on the role of upper endoscopy in the diagnostic work‐up. Dig Dis Sci2012;57:1618. CrossRef

86. WitteAM, VeenendaalRA, Van HogezandRA, et al.Crohn's disease of the upper gastrointestinal tract: the value of endoscopic examination. Scand J Gastroenterol Suppl1998;225:100.

87. DohertyGA, MossAC, CheifetzAS. Capsule endoscopy for small‐bowel evaluation in Crohn's disease. Gastrointest Endosc2011;74:167. CrossRef

88. CheifetzAS, KornbluthAA, LegnaniP, et al.The risk of retention of the capsule endoscope in patients with known or suspected Crohn's disease. Am J Gastroenterol2006;101:2218. CrossRef

89. MurphySJ, KornbluthA. Double balloon enteroscopy in Crohn's disease: where are we now and where should we go?Inflamm Bowel Dis2011;17:485. CrossRef

90. LichtensteinGR, HanauerSB, SandbornWJ. Management of Crohn's disease in adults. Am J Gastroenterol2009;104:465, 4, 84. CrossRef

91. MakhariaGK, SrivastavaS, DasP, et al.Clinical, endoscopic, and histological differentiations between Crohn's disease and intestinal tuberculosis. Am J Gastroenterol2010;105:642. CrossRef

92. YuH, LiuY, WangY, et al.Clinical, endoscopic and histological differentiations between Crohn's disease and intestinal tuberculosis. Digestion2012;85:202. CrossRef

93. BruiningDH, LoftusEVJr, EhmanEC, et al.Computed tomography enterography detects intestinal wall changes and effects of treatment in patients with Crohn's disease. Clin Gastroenterol Hepatol2011;9:679. CrossRef

94. ChatuS, PilcherJ, SaxenaSK, et al.Diagnostic accuracy of small intestine ultrasonography using an oral contrast agent in Crohn's disease: comparative study from the UK. Clin Radiol2012;67:553. CrossRef

95. PaulsenSR, HuprichJE, FletcherJG, et al.CT enterography as a diagnostic tool in evaluating small bowel disorders: review of clinical experience with over 700 cases. Radiographics2006;26:641, 57. CrossRef

96. LeeSS, KimAY, YangSK, et al.Crohn disease of the small bowel: comparison of CT enterography, MR enterography, and small‐bowel follow‐through as diagnostic techniques. Radiology2009;251:751. CrossRef

97. GrandDJ, HarrisA, LoftusEVJr. Imaging for luminal disease and complications: CT enterography, MR enterography, small‐bowel follow‐through, and ultrasound. Gastroenterol Clin North Am2012;41:497. CrossRef

98. RimolaJ, OrdasI, RodriguezS, et al.Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis2011;17:1759. CrossRef

99. ParienteB, CosnesJ, DaneseS, et al.Development of the Crohn's disease digestive damage score, the Lemann score. Inflamm Bowel Dis2011;17:1415. CrossRef

100. MunkholmP, LangholzE, DavidsenM, et al.Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol1995;30:699. CrossRef

101. CosnesJ, CattanS, BlainA, et al.Long‐term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis2002;8:244. CrossRef

102. BeaugerieL, SeksikP, Nion‐LarmurierI, et al.Predictors of Crohn's disease. Gastroenterology2006;130:650. CrossRef

103. Romberg‐CampsMJ, DagneliePC, KesterAD, et al.Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol2009;104:371. CrossRef

104. LolyC, BelaicheJ, LouisE. Predictors of severe Crohn's disease. Scand J Gastroenterol2008;43:948. CrossRef

105. TremaineWJ, TimmonsLJ, LoftusEVJr, et al.Age at onset of inflammatory bowel disease and the risk of surgery for non‐neoplastic bowel disease. Aliment Pharmacol Ther2007;25:1435. CrossRef

106. DuricovaD, PedersenN, ElkjaerM, et al.Overall and cause‐specific mortality in Crohn's disease: a meta‐analysis of population‐based studies. Inflamm Bowel Dis2010;16:347. CrossRef

107. LoftusEVJr. Mortality in inflammatory bowel disease: peril and promise. Gastroenterology2003;125:1881. CrossRef

108. LewisJD, BilkerWB, BrensingerC, et al.Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology2001;121:1080. CrossRef

109. HutflessSM, WengX, LiuL, et al.Mortality by medication use among patients with inflammatory bowel disease, 1996–2003. Gastroenterology2007;133:1779. CrossRef

110. CosnesJ, Nion‐LarmurierI, BeaugerieL, et al.Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut2005;54:237. CrossRef

111. SchoepferAM, BeglingerC, StraumannA, et al.Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES‐CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol2010;105:162. CrossRef

112. D′HaensGR, FedorakR, LemannM, et al.Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflamm Bowel Dis2009;15:1599. CrossRef

113. SandbornWJ, FeaganBG, HanauerSB, et al.A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology2002;122:512. CrossRef

114. GuyattG, MitchellA, IrvineEJ, et al.A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology1989;96:804.

115. SolemCA, LoftusEVJr, TremaineWJ, et al.Correlation of C‐reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis2005;11:707. CrossRef

116. GoodhandJR, KamperidisN, RaoA, et al.Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease. Inflamm Bowel Dis2012;18:513. CrossRef

117. GisbertJP, GomollonF. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol2008;103:1299. CrossRef

118. ArdizzoneS, CassinottiA, BevilacquaM, et al.Vitamin D and inflammatory bowel disease. Vitam Horm2011;86:367. CrossRef

119. AbrahamBP, KaneS. Fecal markers: calprotectin and lactoferrin. Gastroenterol Clin North Am2012;41:483. CrossRef

120. MaoR, XiaoYL, GaoX, et al.Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta‐analysis of prospective studies. Inflamm Bowel Dis2012;18:1894. CrossRef

121. CostaF, MumoloMG, BelliniM, et al.Role of faecal calprotectin as non‐invasive marker of intestinal inflammation. Dig Liver Dis2003;35:642. CrossRef

122. JensenMD, KjeldsenJ, NathanT. Fecal calprotectin is equally sensitive in Crohn's disease affecting the small bowel and colon. Scand J Gastroenterol2011;46:694. CrossRef

123. GradelKO, NielsenHL, SchonheyderHC, et al.Increased short‐ and long‐term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis. Gastroenterology2009;137:495. CrossRef

124. MannEA, SaeedSA. Gastrointestinal infection as a trigger for inflammatory bowel disease. Curr Opin Gastroenterol2012;28:24. CrossRef

125. AnanthakrishnanAN, McGinleyEL, BinionDG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut2008;57:205. CrossRef

126. AnanthakrishnanAN, McGinleyEL, SaeianK, et al.Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis2011;17:976. CrossRef

127. IssaM, VijayapalA, GrahamMB, et al.Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol2007;5:345. CrossRef

128. PrideauxL, De CruzP, NgSC, et al.Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis2012;18:1340. CrossRef

129. IsraeliE, GrottoI, GilburdB, et al.Anti‐Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut2005;54:1232. CrossRef

130. DubinskyMC, LinYC, DutridgeD, et al.Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol2006;101:360. CrossRef

131. ArnottID, LandersCJ, NimmoEJ, et al.Sero‐reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol2004;99:2376. CrossRef

132. DubinskyMC, KugathasanS, MeiL, et al.Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol2008;6:1105. CrossRef

133. RiederF, SchlederS, WolfA, et al.Serum anti‐glycan antibodies predict complicated Crohn's disease behavior: a cohort study. Inflamm Bowel Dis2010;16:1367. CrossRef

134. MelmedGY, FleshnerPR, BardakciogluO, et al.Family history and serology predict Crohn's disease after ileal pouch‐anal anastomosis for ulcerative colitis. Dis Colon Rectum2008;51:100. CrossRef

135. DendrinosKG, BeckerJM, StucchiAF, et al.Anti‐Saccharomyces cerevisiae antibodies are associated with the development of postoperative fistulas following ileal pouch‐anal anastomosis. J Gastrointest Surg2006;10:1060. CrossRef

136. Alvarez‐LobosM, ArosteguiJI, SansM, et al.Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg2005;242:693. CrossRef

137. WeersmaRK, StokkersPC, van BodegravenAA, et al.Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort. Gut2009;58:388. CrossRef

138. HenckaertsL, Van SteenK, VerstrekenI, et al.Genetic risk profiling and prediction of disease course in Crohn's disease patients. Clin Gastroenterol Hepatol2009;7:972. CrossRef

139. VasiliauskasEA, PlevySE, LandersCJ, et al.Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology1996;110:1810. CrossRef

140. IppolitiA, DevlinS, MeiL, et al.Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn's disease. Inflamm Bowel Dis2010;16:1279. CrossRef

141. LouisE, MaryJY, Vernier‐MassouilleG, et al.Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology2012;142:63, e31. CrossRef

142. RutgeertsP, Van AsscheG, SandbornWJ, et al.Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology2012;142:1102. CrossRef

143. MathyC, SchneiderK, ChenYY, et al.Gross versus microscopic pancolitis and the occurrence of neoplasia in ulcerative colitis. Inflamm Bowel Dis2003;9:351. CrossRef

144. SipponenT, SavilahtiE, KolhoKL, et al.Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis2008;14:40. CrossRef

145. ColombelJF, LouisE, Peyrin‐BirouletL, et al.Deep remission: a new concept?Dig Dis2012;30(Suppl 3):107. CrossRef

146. HenriksenM, JahnsenJ, LygrenI, et al.Clinical course in Crohn's disease: results of a five‐year population‐based follow‐up study (the IBSEN study). Scand J Gastroenterol2007;42:602. CrossRef

147. D′HaensG, BaertF, van AsscheG, et al.Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet2008;371:660. CrossRef

148. HyamsJ, CrandallW, KugathasanS, et al.Induction and maintenance infliximab therapy for the treatment of moderate‐to‐severe Crohn's disease in children. Gastroenterology2007;132:863, 1165. CrossRef

149. LichtensteinGR, FeaganBG, CohenRD, et al.Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow‐up in the TREAT registry. Am J Gastroenterol2012;107:1409. CrossRef

150. LimWC, HanauerS. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev2010;(12):CD008870.

151. FordAC, KhanKJ, TalleyNJ, et al.5‐aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta‐analysis. Am J Gastroenterol2011;106:413. CrossRef

152. KrogerAT, SumayaCV, PickeringLK, et al.General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep2011;60 (RR02):1.

153. SellonRK, TonkonogyS, SchultzM, et al.Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin‐10‐deficient mice. Infect Immun1998;66:5224.

154. FriswellM, CampbellB, RhodesJ. The role of bacteria in the pathogenesis of inflammatory bowel disease. Gut Liver2010;4:295. CrossRef

155. PranteraC, KohnA, MangiarottiR, et al.Antimycobacterial therapy in Crohn's disease: results of a controlled, double‐blind trial with a multiple antibiotic regimen. Am J Gastroenterol1994;89:513.

156. BorgaonkarM, MacIntoshD, FardyJ, et al.Anti‐tuberculous therapy for maintaining remission of Crohn's disease. Cochrane Database Syst Rev2000;(2):CD000299.

157. SelbyW, PavliP, CrottyB, et al.Two‐year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology2007;132:2313. CrossRef

158. KhanKJ, UllmanTA, FordAC, et al.Antibiotic therapy in inflammatory bowel disease: a systematic review and meta‐analysis. Am J Gastroenterol2011;106:661. CrossRef

159. SteinhartAH, FeaganBG, WongCJ, et al.Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology2002;123:33. CrossRef

160. SartorRB. Microbial influences in inflammatory bowel diseases. Gastroenterology2008;134:577. CrossRef

161. LeeA, GriffithsTA, ParabRS, et al.Association of Mycobacterium avium subspecies paratuberculosis with Crohn Disease in pediatric patients. J Pediatr Gastroenterol Nutr2011;52:170. CrossRef

162. Di SabatinoA, PaccagniniD, VidaliF, et al.Detection of Mycobacterium avium subsp. paratuberculosis (MAP)‐specific IS900 DNA and antibodies against MAP peptides and lysate in the blood of Crohn's disease patients. Inflamm Bowel Dis2011;17:1254. CrossRef

163. SandersME, GuarnerF, GuerrantR, et al.An update on the use and investigation of probiotics in health and disease. Gut2013;62:787. CrossRef

164. FaubionWAJr, LoftusEVJr, HarmsenWS, et al.The natural history of corticosteroid therapy for inflammatory bowel disease: a population‐based study. Gastroenterology2001;121:255. CrossRef

165. SummersRW, SwitzDM, SessionsJTJr, et al.National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology1979;77:847.

166. MalchowH, EweK, BrandesJW, et al.European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology1984;86:249.

167. LindorKD, FlemingCR, BurnesJU, et al.A randomized prospective trial comparing a defined formula diet, corticosteroids, and a defined formula diet plus corticosteroids in active Crohn's disease. Mayo Clin Proc1992;67:328. CrossRef

168. ModiglianiR, MaryJY, SimonJF, et al.Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d′Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology1990;98:811. CrossRef

169. SteinhartAH, EweK, GriffithsAM, et al.Corticosteroids for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev2003;(4):CD000301.

170. BrignolaC, De SimoneG, BelloliC, et al.Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration. Aliment Pharmacol Ther1994;8:465. CrossRef

171. KaneSV, SchoenfeldP, SandbornWJ, et al.The effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther2002;16:1509. CrossRef

172. GreenbergGR, FeaganBG, MartinF, et al.Oral budesonide as maintenance treatment for Crohn's disease: a placebo‐controlled, dose‐ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology1996;110:45. CrossRef

173. GreenbergGR, FeaganBG, MartinF, et al.Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med1994;331:836. CrossRef

174. PrefontaineE, MacdonaldJK, SutherlandLR. Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev2010;(6):CD000545.

175. SandbornWJ, TremaineWJ, WolfDC, et al.Lack of effect of intravenous administration on time to respond to azathioprine for steroid‐treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology1999;117:527. CrossRef

176. TretonX, BouhnikY, MaryJY, et al.Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol2009;7:80. CrossRef

177. Peyrin‐BirouletL, KhosrotehraniK, CarratF, et al.Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology2011;141:1621. CrossRef

178. DubinskyMC, LamotheS, YangHY, et al.Pharmacogenomics and metabolite measurement for 6‐mercaptopurine therapy in inflammatory bowel disease. Gastroenterology2000;118:705. CrossRef

179. ShayeOA, YadegariM, AbreuMT, et al.Hepatotoxicity of 6‐mercaptopurine (6‐MP) and Azathioprine (AZA) in adult IBD patients. Am J Gastroenterol2007;102:2488. CrossRef

180. WeinshilboumRM, SladekSL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet1980;32:651.

181. DubinskyMC, ReyesE, OfmanJ, et al.A cost‐effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6‐mercaptopurine. Am J Gastroenterol2005;100:2239. CrossRef

182. FeaganBG, RochonJ, FedorakRN, et al.Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med1995;332:292. CrossRef

183. FeaganBG, FedorakRN, IrvineEJ, et al.A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med2000;342:1627. CrossRef

184. McDonaldJW, TsoulisDJ, MacdonaldJK, et al.Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev2012;(12):CD003459.

185. PatelV, MacdonaldJK, McDonaldJW, et al.Methotrexate for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev2009;(4):CD006884.

186. SparrowMP, HandeSA, FriedmanS, et al.Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6‐mercaptopurine. Clin Gastroenterol Hepatol2007;5:209. CrossRef

187. ShihDQ, NguyenM, ZhengL, et al.Split‐dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6‐MMP metabolism. Aliment Pharmacol Ther2012;36:449. CrossRef

188. BrynskovJ, FreundL, RasmussenSN, et al.A placebo‐controlled, double‐blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med1989;321:845. CrossRef

189. FeaganBG, McDonaldJW, RochonJ, et al.Low‐dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators. N Engl J Med1994;330:1846. CrossRef

190. McSharryK, DalzellAM, LeiperK, et al.Systematic review: the role of tacrolimus in the management of Crohn's disease. Aliment Pharmacol Ther2011;34:1282. CrossRef

191. SandbornWJ, PresentDH, IsaacsKL, et al.Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo‐controlled trial. Gastroenterology2003;125:380. CrossRef

192. HartAL, PlamondonS, KammMA. Topical tacrolimus in the treatment of perianal Crohn's disease: exploratory randomized controlled trial. Inflamm Bowel Dis2007;13:245. CrossRef

193. Peyrin‐BirouletL, DeltenreP, de SurayN, et al.Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta‐analysis of placebo‐controlled trials. Clin Gastroenterol Hepatol2008;6:644. CrossRef

194. BehmBW, BickstonSJ. Tumor necrosis factor‐alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev2008;(1):CD006893.

195. FordAC, SandbornWJ, KhanKJ, et al.Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta‐analysis. Am J Gastroenterol2011;106:644, 60. CrossRef

196. LichtigerS, BinionDG, WolfDC, et al.The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. Aliment Pharmacol Ther2010;32:1228. CrossRef

197. BinionDG, LouisE, OldenburgB, et al.Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn's disease: a meta‐analysis. Can J Gastroenterol2011;25:492.

198. FeaganBG, CoteurG, TanS, et al.Clinically meaningful improvement in health‐related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease. Am J Gastroenterol2009;104:1976. CrossRef

199. FeaganBG, ReillyMC, GerlierL, et al.Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate‐to‐severe Crohn's disease in the PRECiSE 2 study. Aliment Pharmacol Ther2010;31:1276. CrossRef

200. HebuterneX, LemannM, BouhnikY, et al.Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut2013;62:201. CrossRef

201. FeaganBG, PanaccioneR, SandbornWJ, et al.Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology2008;135:1493. CrossRef

202. LeombrunoJP, NguyenGC, GrootendorstP, et al.Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysis. Pharmacoepidemiol Drug Saf2011;20:838. CrossRef

203. HyamsJS, GriffithsA, MarkowitzJ, et al.Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology2012;143:365. CrossRef

204. SandsBE, BlankMA, PatelK, et al.Long‐term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol2004;2:912. CrossRef

205. Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep2011;60(01):13.

206. WestRL, van der WoudeCJ, HansenBE, et al.Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double‐blind placebo‐controlled study. Aliment Pharmacol Ther2004;20:1329. CrossRef

207. RegueiroM, SchrautW, BaidooL, et al.Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology2009;136:441, 716. CrossRef

208. BrooklynTN, DunnillMG, ShettyA, et al.Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut2006;55:505. CrossRef

209. Cordero‐ComaM, YilmazT, OnalS. Systematic review of anti‐tumor necrosis factor‐alpha therapy for treatment of immune‐mediated uveitis. Ocul Immunol Inflamm2013;21:19. CrossRef

210. ColombelJF, SandbornWJ, ReinischW, et al.Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med2010;362:1383. CrossRef

211. TorunerM, LoftusEVJr, HarmsenWS, et al.Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology2008;134:929. CrossRef

212. BeaugerieL. Inflammatory bowel disease therapies and cancer risk: where are we and where are we going?Gut2012;61:476. CrossRef

213. MelmedGY, SpiegelBM, BresslerB, et al.The appropriateness of concomitant immunomodulators with anti‐tumor necrosis factor agents for Crohn's disease: one size does not fit all. Clin Gastroenterol Hepatol2010;8:655. CrossRef

214. BelardE, SembS, RuhwaldM, et al.Prednisolone treatment affects the performance of the QuantiFERON gold in‐tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis2011;17:2340. CrossRef

215. MowWS, Abreu‐MartinMT, PapadakisKA, et al.High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol2004;2:309. CrossRef

216. ChungES, PackerM, LoKH, et al.Randomized, double‐blind, placebo‐controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor‐alpha, in patients with moderate‐to‐severe heart failure: results of the anti‐TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation2003;107:3133. CrossRef

217. TungJ, LoftusEVJr, FreeseDK, et al.A population‐based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis2006;12:1093. CrossRef

218. DretzkeJ, EdlinR, RoundJ, et al.A systematic review and economic evaluation of the use of tumour necrosis factor‐alpha (TNF‐alpha) inhibitors, adalimumab and infliximab, for Crohn's disease. Health Technol Assess2011;15:1. CrossRef

219. MelmedGY, SiegelCA, SpiegelBM, et al.Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis2013;19:662. CrossRef

220. MelmedGY. Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. Inflamm Bowel Dis2009;15:1410. CrossRef

221. ParsiMA, AchkarJP, RichardsonS, et al.Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology2002;123:707. CrossRef

222. ParsiMA. Does smoking decrease the response to infliximab in patients with Crohn's disease?Inflamm Bowel Dis2008;14(Suppl 2):S18. CrossRef

223. ReinischW, WangY, OddensBJ, et al.C‐reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post‐hoc analysis from ACCENT I. Aliment Pharmacol Ther2012;35:568. CrossRef

224. JurgensM, Mahachie JohnJM, CleynenI, et al.Levels of C‐reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol2011;9:421. CrossRef

225. LouisE, VermeireS, RutgeertsP, et al.A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with ‐308 TNF gene polymorphism. Scand J Gastroenterol2002;37:818. CrossRef

226. EstersN, VermeireS, JoossensS, et al.Serological markers for prediction of response to anti‐tumor necrosis factor treatment in Crohn's disease. Am J Gastroenterol2002;97:1458. CrossRef

227. TaylorKD, PlevySE, YangH, et al.ANCA pattern and LTA haplotype relationship to clinical responses to anti‐TNF antibody treatment in Crohn's disease. Gastroenterology2001;120:1347. CrossRef

228. DubinskyMC, MeiL, FriedmanM, et al.Genome wide association (GWA) predictors of anti‐TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease. Inflamm Bowel Dis2010;16:1357. CrossRef

229. HlavatyT, PierikM, HenckaertsL, et al.Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment Pharmacol Ther2005;22:613. CrossRef

230. SandbornWJ, ColombelJF, EnnsR, et al.Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med2005;353:1912. CrossRef

231. TarganSR, FeaganBG, FedorakRN, et al.Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology2007;132:1672. CrossRef

232. AdelmanB, SandrockA, PanzaraMA. Natalizumab and progressive multifocal leukoencephalopathy. N Engl J Med2005;353:432. CrossRef

233. BloomgrenG, RichmanS, HotermansC, et al.Risk of natalizumab‐associated progressive multifocal leukoencephalopathy. N Engl J Med2012;366:1870. CrossRef

234. HanauerSB, FeaganBG, LichtensteinGR, et al.Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet2002;359:1541. CrossRef

235. ColombelJF, SandbornWJ, RutgeertsP, et al.Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology2007;132:52. CrossRef

236. SandbornWJ, HanauerSB, RutgeertsP, et al.Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut2007;56:1232. CrossRef

237. GisbertJP, PanesJ. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol2009;104:760. CrossRef

238. BillioudV, SandbornWJ, Peyrin‐BirouletL. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol2011;106:674. CrossRef

239. BaertF, GlorieusE, ReenaersC, et al.Adalimumab dose escalation and dose de‐escalation success rate and predictors in a large national cohort of Crohn's patients. J Crohns Colitis2013;7:154. CrossRef

240. AllezM, KarmirisK, LouisE, et al.Report of the ECCO pathogenesis workshop on anti‐TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis2010;4:355. CrossRef

241. ChowersY, SturmA, SansM, et al.Report of the ECCO workshop on anti‐TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists. J Crohns Colitis2010;4:367. CrossRef

242. OrdasI, MouldDR, FeaganBG, et al.Anti‐TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics‐based dosing paradigms. Clin Pharmacol Ther2012;91:635. CrossRef

243. BaertF, NomanM, VermeireS, et al.Influence of immunogenicity on the long‐term efficacy of infliximab in Crohn's disease. N Engl J Med2003;348:601. CrossRef

244. DaneseS, FiorinoG, ReinischW. Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti‐TNF‐alpha therapy. Aliment Pharmacol Ther2011;34:1. CrossRef

245. ClarkM, ColombelJF, FeaganBC, et al.American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21–23, 2006. Gastroenterology2007;133:312. CrossRef

246. KarmirisK, PaintaudG, NomanM, et al.Influence of trough serum levels and immunogenicity on long‐term outcome of adalimumab therapy in Crohn's disease. Gastroenterology2009;137:1628. CrossRef

247. HanauerSB, WagnerCL, BalaM, et al.Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol2004;2:542. CrossRef

248. MaserEA, VillelaR, SilverbergMS, et al.Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol2006;4:1248. CrossRef

249. AfifW, LoftusEVJr, FaubionWA, et al.Clinical utility of measuring infliximab and human anti‐chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol2010;105:1133. CrossRef

250. SeowCH, NewmanA, IrwinSP, et al.Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut2010;59:49. CrossRef

251. FarrellRJ, AlsahliM, JeenYT, et al.Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology2003;124:917. CrossRef

252. CleynenI, Mahachie JohnJM, HenckaertsL, et al.Molecular reclassification of Crohn's disease by cluster analysis of genetic variants. PLoS ONE2010;5:e12952. CrossRef

253. YarurA, DeshpandeAR, SussmanDA, et al. Serum adalimumab levels and antibodies correlate with endoscopic intestinal inflammation and inflammatory markers in patients with inflammatory bowel disease. Gastroenterology2013;144 (Suppl):S774. CrossRef

254. VelayosFS, Sheibani S, LocktonS, et al.Prevalence of antibodies to adalimumab (ATA) and significance of ATA/drug concentration on CRP and symptoms in unselected IBD patients. Gastroenterology2013;144 (Suppl):S91. CrossRef

255. BaertF, VermeireS, GilsA. Loss of response to anti‐TNF monoclonal antibodies: mechanisms, assessment, and management. Inflamm Bowel Dis Monit2012;13:1.

256. VelayosFS, KahnJG, SandbornWJ, et al.A test‐based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol2013;11:654. CrossRef

257. SandbornWJ, SchreiberS, HanauerSB, et al.Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol2010;8:696. CrossRef

258. FeaganBG, SandbornWJ, WolfDC, et al.Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. Aliment Pharmacol Ther2011;33:541. CrossRef

259. Peyrin‐BirouletL, HarmsenWS, TremaineWJ, et al.Surgery in a population‐based cohort of Crohn's disease from Olmsted County, Minnesota (1970–2004). Am J Gastroenterol2012;107:1693. CrossRef

260. RamadasAV, GuneshS, ThomasGA, et al.Natural history of Crohn's disease in a population‐based cohort from Cardiff (1986–2003): a study of changes in medical treatment and surgical resection rates. Gut2010;59:1200. CrossRef

261. RutgeertsP, GeboesK, VantrappenG, et al.Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut1984;25:665. CrossRef

262. OlaisonG, SmedhK, SjodahlR. Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut1992;33:331. CrossRef

263. UnkartJT, AndersonL, LiE, et al.Risk factors for surgical recurrence after ileocolic resection of Crohn's disease. Dis Colon Rectum2008;51:1211. CrossRef

264. SacharDB, LemmerE, IbrahimC, et al.Recurrence patterns after first resection for stricturing or penetrating Crohn's disease. Inflamm Bowel Dis2009;15:1071. CrossRef

265. DohertyGA, BennettGC, CheifetzAS, et al.Meta‐analysis: targeting the intestinal microbiota in prophylaxis for post‐operative Crohn's disease. Aliment Pharmacol Ther2010;31:802.

266. RutgeertsP, HieleM, GeboesK, et al.Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology1995;108:1617. CrossRef

267. RutgeertsP, Van AsscheG, VermeireS, et al.Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double‐blind, placebo‐controlled trial. Gastroenterology2005;128:856. CrossRef

268. Peyrin‐BirouletL, DeltenreP, ArdizzoneS, et al.Azathioprine and 6‐mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta‐analysis. Am J Gastroenterol2009;104:2089. CrossRef

269. RegueiroM. Postoperative Crohn's Disease Recurrence and Prevention. Thorofare, NJ: Slack, Inc.; 2013.

270. PapamichaelK, ArchavlisE, LariouC, et al.Adalimumab for the prevention and/or treatment of post‐operative recurrence of Crohn's disease: a prospective, two‐year, single center, pilot study. J Crohns Colitis2012;6:924. CrossRef

271. YamamotoT, UmegaeS, MatsumotoK. Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: a prospective pilot study. Inflamm Bowel Dis2009;15:1460. CrossRef

272. SchwartzM, RegueiroM. Prevention and treatment of postoperative Crohn's disease recurrence: an update for a new decade. Curr Gastroenterol Rep2011;13:95. CrossRef

273. LongMD, MartinC, SandlerRS, et al.Increased risk of pneumonia among patients with inflammatory bowel disease. Am J Gastroenterol2013;108:240. CrossRef

274. LongMD, FarrayeFA, OkaforPN, et al.Increased risk of pneumocystis jiroveci pneumonia among patients with inflammatory bowel disease. Inflamm Bowel Dis2013;19:1018. CrossRef

275. LongMD, MartinC, SandlerRS, et al.Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease. Aliment Pharmacol Ther2013;37:420. CrossRef

276. GuptaG, LautenbachE, LewisJD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol2006;4:1483. CrossRef

277. National Center for Immunization and Respiratory Diseases. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep2011;60(RR02):1.

278. ZhangJ, XieF, DelzellE, et al.Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune‐mediated diseases. JAMA2012;308:43.

279. ZhangJ, DelzellE, XieF, et al.The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. Arthritis Res Ther2011;13:R174. CrossRef

280. CanavanC, AbramsKR, MayberryJ. Meta‐analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther2006;23:1097. CrossRef

281. KappelmanMD, FarkasDK, LongMD, et al.Risk of cancer in patients with inflammatory bowel diseases: a nationwide population‐based cohort study with 30 years of follow‐up evaluation. Clin Gastroenterol Hepatol2014;12:265. CrossRef

282. SiegelCA, MardenSM, PersingSM, et al.Risk of lymphoma associated with combination anti‐tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta‐analysis. Clin Gastroenterol Hepatol2009;7:874. CrossRef

283. LongMD, MartinCF, PipkinCA, et al.Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology2012;143:390. CrossRef

284. Peyrin‐BirouletL, LoftusEVJr, ColombelJF, et al.Long‐term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population‐based cohorts. Inflamm Bowel Dis2011;17:471. CrossRef

285. SoderlundS, BrandtL, LapidusA, et al.Decreasing time‐trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology2009;136:1561, 818. CrossRef

286. JessT, LoftusEVJr, VelayosFS, et al.Risk of intestinal cancer in inflammatory bowel disease: a population‐based study from olmsted county, Minnesota. Gastroenterology2006;130:1039. CrossRef

287. von RoonAC, ReeseG, TeareJ, et al.The risk of cancer in patients with Crohn's disease. Dis Colon Rectum2007;50:839. CrossRef

288. KotlyarDS, OstermanMT, DiamondRH, et al.A systematic review of factors that contribute to hepatosplenic T‐cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol2011;9:36. CrossRef

289. LoftusEVJr, TremaineWJ, HabermannTM, et al.Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol2000;95:2308. CrossRef

290. SiegelCA, MardenSM, PersingSM, et al.Risk of lymphoma associated with combination Anti‐TNF and immunomodulator therapy for the treatment of crohn's disease: a meta‐analysis. Clin Gastroenterol Hepatol2009;7:874. CrossRef

291. DayharshGA, LoftusEVJr, SandbornWJ, et al.Epstein‐Barr virus‐positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6‐mercaptopurine. Gastroenterology2002;122:72. CrossRef

292. RoshJR, GrossT, MamulaP, et al.Hepatosplenic T‐cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?Inflamm Bowel Dis2007;13:1024. CrossRef

293. HerrintonLJ, LiuL, AbramsonO, et al.The incidence of hepatosplenic T‐cell lymphoma in a large managed care organization, with reference to anti‐tumor necrosis factor therapy, Northern California, 2000–2006. Pharmacoepidemiol Drug Saf2012;21:49. CrossRef

294. LongMD, HerfarthHH, PipkinCA, et al.Increased risk for non‐melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol2010;8:268. CrossRef

295. SinghAB, SharmaA, SmithJJ, et al.Claudin‐1 up‐regulates the repressor ZEB‐1 to inhibit E‐cadherin expression in colon cancer cells. Gastroenterology2011;141:2140. CrossRef

296. MoscandrewM, MahadevanU, KaneS. General health maintenance in IBD. Inflamm Bowel Dis2009;15:1399. CrossRef

297. LichtensteinGR, AbreuMT, CohenR, et al.American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology2006;130:940. CrossRef

298. SzigethyB. Psychiatric Complications in IBD. Thorofare, NJ: Slack, Inc.; 2013.

299. DuffyLC, ZieleznyMA, MarshallJR, et al.Relevance of major stress events as an indicator of disease activity prevalence in inflammatory bowel disease. Behav Med1991;17:101. CrossRef

300. NorthCS, AlpersDH, HelzerJE, et al.Do life events or depression exacerbate inflammatory bowel disease? A prospective study. Ann Intern Med1991;114:381. CrossRef

301. MaunderRG, GreenbergGR, NolanRP, et al.Autonomic response to standardized stress predicts subsequent disease activity in ulcerative colitis. Eur J Gastroenterol Hepatol2006;18:413. CrossRef

302. GoodhandJR, WahedM, RamptonDS. Management of stress in inflammatory bowel disease: a therapeutic option?Expert Rev Gastroenterol Hepatol2009;3:661. CrossRef

303. EngstromI. Mental health and psychological functioning in children and adolescents with inflammatory bowel disease: a comparison with children having other chronic illnesses and with healthy children. J Child Psychol Psychiatry1992;33:563. CrossRef

304. LereboursE, Gower‐RousseauC, MerleV, et al.Stressful life events as a risk factor for inflammatory bowel disease onset: a population‐based case‐control study. Am J Gastroenterol2007;102:122. CrossRef

305. NicholasDB, SwanSR, GerstleTJ, et al.Struggles, strengths, and strategies: an ethnographic study exploring the experiences of adolescents living with an ostomy. Health Qual Life Outcomes2008;6:114. CrossRef

306. SewitchMJ, AbrahamowiczM, BittonA, et al.Psychological distress, social support, and disease activity in patients with inflammatory bowel disease. Am J Gastroenterol2001;96:1470. CrossRef

307. TaftTH, KeeferL, LeonhardC, et al.Impact of perceived stigma on inflammatory bowel disease patient outcomes. Inflamm Bowel Dis2009;15:1224. CrossRef

308. DrossmanDA, LesermanJ, LiZM, et al.The rating form of IBD patient concerns: a new measure of health status. Psychosom Med1991;53:701. CrossRef

309. OliveiraS, ZaltmanC, EliaC, et al.Quality‐of‐life measurement in patients with inflammatory bowel disease receiving social support. Inflamm Bowel Dis2007;13:470. CrossRef

310. ZachosM, TondeurM, GriffithsAM. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst Rev2007;(1):CD000542.

311. VasseurF, Gower‐RousseauC, Vernier‐MassouilleG, et al.Nutritional status and growth in pediatric Crohn's disease: a population‐based study. Am J Gastroenterol2010;105:1893. CrossRef

312. LongMD, CrandallWV, LeibowitzIH, et al.Prevalence and epidemiology of overweight and obesity in children with inflammatory bowel disease. Inflamm Bowel Dis2011;17:2162. CrossRef

313. Nic SuibhneT, RafteryTC, McMahonO, et al.High prevalence of overweight and obesity in adults with Crohn's disease: associations with disease and lifestyle factors. J Crohns Colitis2013;7:e241. CrossRef

314. AttardTM, HortonKM, DeVitoK, et al.Pediatric jejunoileitis: a severe Crohn's disease phenotype that requires intensive nutritional management. Inflamm Bowel Dis2004;10:357. CrossRef

315. IrvingPM, PasiKJ, RamptonDS. Thrombosis and inflammatory bowel disease. Clin Gastroenterol Hepatol2005;3:617. CrossRef

316. JeppesenPB, PertkiewiczM, MessingB, et al.Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology2012;143:1473. CrossRef

317. HeikensJT, de VriesJ, van LaarhovenCJ. Quality of life, health‐related quality of life and health status in patients having restorative proctocolectomy with ileal pouch‐anal anastomosis for ulcerative colitis: a systematic review. Colorectal Dis2012;14:536. CrossRef

318. HahnloserD, PembertonJH, WolffBG, et al.Results at up to 20 years after ileal pouch‐anal anastomosis for chronic ulcerative colitis. Br J Surg2007;94:333. CrossRef

319. AlexanderF, SarigolS, DiFioreJ, et al.Fate of the pouch in 151 pediatric patients after ileal pouch anal anastomosis. J Pediatr Surg2003;38:78. CrossRef

320. ShenB, RemziFH, LaveryIC, et al.A proposed classification of ileal pouch disorders and associated complications after restorative proctocolectomy. Clin Gastroenterol Hepatol2008;6:145, 24. CrossRef

321. WolfJM, AchkarJP, LashnerBA, et al.Afferent limb ulcers predict Crohn's disease in patients with ileal pouch‐anal anastomosis. Gastroenterology2004;126:1686. CrossRef

322. Barreiro‐de AcostaM, Garcia‐BoschO, SoutoR, et al.Efficacy of infliximab rescue therapy in patients with chronic refractory pouchitis: a multicenter study. Inflamm Bowel Dis2012;18:812. CrossRef

323. MazoyerE, SzetoKC, BassetJM, et al.High selectivity production of propylene from 2‐butene: non‐degenerate pathways to convert symmetric olefins via olefin metathesis. Chem Commun (Camb)2012;48:3611. CrossRef

324. FerranteM, D′HaensG, DewitO, et al.Efficacy of infliximab in refractory pouchitis and Crohn's disease‐related complications of the pouch: a Belgian case series. Inflamm Bowel Dis2010;16:243. CrossRef

325. NavaneethanU, VenkateshPG, BennettAE, et al.Impact of budesonide on liver function tests and gut inflammation in patients with primary sclerosing cholangitis and ileal pouch anal anastomosis. J Crohns Colitis2012;6:536. CrossRef

326. FazioVW, KiranRP, RemziFH, et al.Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients. Ann Surg2013;257:679. CrossRef

327. HartleyJE, FazioVW, RemziFH, et al.Analysis of the outcome of ileal pouch‐anal anastomosis in patients with Crohn's disease. Dis Colon Rectum2004;47:1808. CrossRef

328. LeQ, MelmedG, DubinskyM, et al.Surgical outcome of ileal pouch‐anal anastomosis when used intentionally for well‐defined Crohn's disease. Inflamm Bowel Dis2013;19:30. CrossRef

329. JoyceMR, FazioVW. Can ileal pouch anal anastomosis be used in Crohn's disease?Adv Surg2009;43:111. CrossRef

330. MahadevanU, CucchiaraS, HyamsJS, et al.The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol2011;106:214, 24. CrossRef

331. MoralesM, BerneyT, JennyA, et al.Crohn's disease as a risk factor for the outcome of pregnancy. Hepatogastroenterology2000;47:1595.

332. BushMC, PatelS, LapinskiRH, et al.Perinatal outcomes in inflammatory bowel disease. J Matern Fetal Neonatal Med2004;15:237. CrossRef

333. FedorkowDM, PersaudD, NimrodCA. Inflammatory bowel disease: a controlled study of late pregnancy outcome. Am J Obstet Gynecol1989;160:998. CrossRef

334. ReddyD, MurphySJ, KaneSV, et al.Relapses of inflammatory bowel disease during pregnancy: in‐hospital management and birth outcomes. Am J Gastroenterol2008;103:1203. CrossRef

335. MahadevanU, SandbornWJ, LiDK, et al.Pregnancy outcomes in women with inflammatory bowel disease: a large community‐based study from Northern California. Gastroenterology2007;133:1106. CrossRef

336. NorgardB, HundborgHH, JacobsenBA, et al.Disease activity in pregnant women with Crohn's disease and birth outcomes: a regional Danish cohort study. Am J Gastroenterol2007;102:1947. CrossRef

337. MahadevanU, WolfDC, DubinskyM, et al.Placental transfer of anti‐tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol2013;11:286, e24. CrossRef

338. SchnitzlerF, FidderH, FerranteM, et al.Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis2011;17:1846. CrossRef

339. HellerMM, WuJJ, MuraseJE. Fatal case of disseminated BCG infection after vaccination of an infant with in utero exposure to infliximab. J Am Acad Dermatol2011;65:870. CrossRef

340. Ben‐HorinS, YavzoriM, KatzL, et al.Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol2010;8:475. CrossRef

341. FrolkisA, DielemanLA, BarkemaH, et al.Environment and the inflammatory bowel diseases. Can J Gastrol2013;27:e18.